Halozyme (HALO) Secures Injunction Blocking Keytruda SC in Parts of Europe

Halozyme won a Dutch court order against Merck, halting the sale and production of Keytruda SC in eight European markets. The ruling found Merck infringed Halozyme's patent for under-the-skin drug delivery. Merck plans to evaluate next steps and disputes the decision. Halozyme has also sued Merck in the U.S. and Germany.

Halozyme Therapeutics won a court order blocking Merck from manufacturing and distributing a formulation of its cancer drug, Keytruda SC, in several European markets. The Dutch patent court ruled Merck infringed Halozyme's patent, following a similar injunction in Germany. Merck disputes the ruling and plans to appeal.

Halozyme Therapeutics (HALO) announced a Dutch court ruled Merck (MRK) infringed its patent and barred sales of Keytruda SC in eight European markets. The injunction prohibits Merck from manufacturing, selling, or distributing the drug in those countries.

Halozyme Therapeutics' stock rose 0.8% after a Dutch court ruled Merck infringed its patent, halting Keytruda SC sales in eight European markets. The court also upheld the patent's validity. Halozyme also expanded its collaboration with argenx, increasing royalty and milestone revenue potential. H.C. Wainwright reiterated a Buy rating with a $115 price target. The stock's gains contrast with broader market declines, reflecting investor confidence in its ENHANZE technology and patent strategy.

Halozyme Therapeutics (HALO) shares rose 2% after winning a patent injunction against Merck's Keytruda SC in multiple European markets. The Dutch court ruled Merck infringed Halozyme's patent and ordered a halt to Keytruda SC's activities in those regions. Halozyme's legal action is part of a global effort to protect its MDASE technology. H.C. Wainwright reiterated a Buy rating and $115 price target for HALO.

Halozyme Therapeutics (HALO) won a Dutch court case against Merck, halting Merck's Keytruda SC in eight European countries. HALO's stock is trading at $112.16, 10.8% above its GF Value of $101.24, with a GF Score of 89. Insiders sold $41.8M in shares over the past year. The ruling may delay Merck's market entry, preserving HALO's licensing revenue.